platoseedplatoseed
Regulating the immune system to block cancer & autoimmune diseases
SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents.
SFA Therapeutics is developing an oral immune tolerance therapy (SFA-002) aimed at resetting the gut-immune axis to treat psoriasis by targeting underlying immune dysfunction rather than broad immunosuppression. The program emphasizes a deuterated short-chain fatty acid platform with Phase 2 in planning and multiple pipeline candidates.
SFA-002 is an oral once-daily deuterated short-chain fatty acid designed to reach the gut and modulate the immune system, upregulating IL-10 and expanding regulatory T cells to reduce inflammatory cytokines (IL-17, IL-23, IFN-γ, TNF) and reset immunity. The company describes a four-step mechanism: oral administration to the gut, IL-10 upregulation, T-reg expansion, and sustained immune reset, with Phase 1b open-label data showing safety and efficacy signals in plaque psoriasis. The pipeline also includes SFA-009 and SFA-001 in preclinical/early-stage programs targeting other cancers and liver disease, respectively, with future autoimmune indications anticipated.
Who it’s for: Healthcare innovators and biotechnology/pharmaceutical companies seeking targeted immune-modulation therapies for psoriasis and other autoimmune diseases; investors and partners interested in oral immune-tolerance platforms.
Phase 2 in preparation; multiple pipeline programs in preclinical/early clinical stages; ongoing emphasis on investigational therapies and regulatory disclosures
Dr. Spector is the co-founder of SFA, a microbiome-derived pharmaceutical company focused on new advancements in the treatment inflammatory diseases. An experienced drug developer with over 30 years of experience, he helped develop 34 drugs and 12 medical devices, including Enbrel, Effexor, Protonix, Prevenar, Ozurdex, Botox for Overactive Bladder, Chronic Migraine and Cerebral Palsy. He holds BS degrees in Physics and EE from Washington University, an MBA from Drexel, and a PhD from Rutgers.
MS is Microbiology, PhD in Biotechnology, Assistant Professor at Temple University, Co-Founder and Co-Inventor at SFA Therapeutics, Inc. Performed a case-control, Proof-of-Activity Human study to evaluate treatment effect of SFA002 drug (proprietary of SFA Therapeutics, Inc.) on patients with plaque psoriasis. Worked with Axella Research on pre-IND application for SFA002. Worked with HEC (Sunshine Lake Pharma Co., China), Theravectys, and ThirdLaw LLC (still collaborating with the latter)
Mark Feitelson received his Ph.D. in Microbiology/Immunology from UCLA. He began his work with hepatitis B at Stanford University, and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). In 1991, Dr. Feitelson moved to Thomas Jefferson University, and in 2007, to Temple University as a Professor of Biology. His work has been supported by NIH, industry and foundations. He has more than 150 publications and 180 abstracts. He is also CSO of SFA Therapeutics.
A therapeutics platform for curing inflammatory disorders
Altay develops disease-modifying therapies targeting transcription…
